Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Symbollon Pharmaceuticals has completed Phase III pivotal trial to evaluate the effectiveness of IoGen for moderate to severe cyclic pain and tenderness associated with fibrocystic breast disease.
Subscribe to our email newsletter
With the last of the 140 patients randomized in the trial having completed the dosing stage of the study, Symbollon is focused on closing the database. The company anticipates that the database will be locked in March 2008 and plans to release the trial results at that time.
Paul Desjourdy, president and CEO of Symbollon, said: “The current Phase III study will help determine whether IoGen can be commercialized as the first non-hormonal drug approved to treat women suffering from FBD.”